05.06.2011 James M. Burns Comments on Federal Trade Commission Report Jim Burns was recently interviewed by the BNA Pharmaceutical Law and Industry Reporter regarding the Federal Trade Commission's May 3 report on "pay for delay" drug patent settlements. In the publication's May 6 issue, Jim notes that the FTC's report will likely bolster its efforts to obtain a legislative prohibition on such settlements, which the FTC claims are anticompetitive and have cost consumers billions in increased drug costs. The FTC's focus on a legislative solution follows its lack of success in challenging these settlements in the courts. A link to the article can be found here.